Alignment with the FDA enables a Q4 NDA submission for AXPAXLI in wet AMD, leveraging strong single-trial data and the 505(b)(2) pathway. The product shows superior durability, robust safety, and is expected to see broad adoption, with commercial and financial readiness in place.Based on Ocular The…
Alignment with the FDA enables a planned Q4 NDA submission for AXPAXLI, supported by robust single-trial data showing superior durability and safety in wet AMD. Commercial and operational infrastructure is in place, with broad adoption expected and strong financial resources backing the launch.Base…
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. NASDAQ:OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.Upcoming Scien…
